Sign in
TRIL Stock Price, Chart, Stats & News
Trillium Therapeutics Inc.
Save
Trillium Therapeutics Inc. (TRIL) does not currently pay a dividend.
–
Market cap
–
Current P/E
–
Forward P/E
TRIL chart
1M
3M
1Y
5Y
Loading chart...
About
Health care
Sector
Biotechnology
Industry
Trillium Therapeutics Inc. is a clinical-stage biotechnology firm specializing in immuno-oncology, dedicated to discovering and developing innovative cancer treatments. Its leading experimental therapy, TTI-621, is a SIRPaFc fusion protein engineered to function as a soluble decoy receptor, effectively blocking the inhibitory signaling pathway of CD47. This compound is currently undergoing Phase I clinical evaluations for patients suffering from advanced, recurrent, or treatment-resistant hematological cancers, as well as solid tumors and mycosis fungoides.
Similar securities
Based on sector and market capitalization
Report issue